Results 181 to 190 of about 436,330 (367)

Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic dermatitis: A population-based cohort study [PDF]

Serena Yun‐Chen Tsai, Wanda Phipatanakul, Elena B. Hawryluk, Michiko K. Oyoshi, Lynda C. Schneider, Kevin Sheng‐Kai   +5 more
openalex   +1 more source

Constitutive NF-κB Activation Confers Interleukin 6 (IL6) Independence and Resistance to Dexamethasone and Janus Kinase Inhibitor INCB018424 in Murine Plasmacytoma Cells [PDF]

, 2011
Yanqiang Yang, Jason S. Groshong, Hittu Matta, Gopalakrishnan Ramakrishnan, Han Yi, Preet M. Chaudhary   +5 more
openalex   +1 more source

Successful Treatment of Paediatric Necrobiosis Lipoidica With Baricitinib

JEADV Clinical Practice, EarlyView.
ABSTRACT Necrobiosis lipoidica (NL) is a rare, chronic granulomatous condition that typically presents as sharply demarcated plaques with telangiectasia and atrophic centres. Paediatric cases are uncommon, and treatment options often fail to address refractory cases.
P. Simões Farinha, M. J. Paiva‐Lopes
wiley   +1 more source

Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis

Journal of Inflammation Research, 2013
Maurizio Cutolo, Marianna Meroni Research Laboratories and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy Abstract: Immune/inflammatory cells act in rheumatoid arthritis (RA)-affected ...
Cutolo M, Meroni M
doaj  

Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines

, 2016
Eugene Guorong Yang, Nurulhuda Mustafa, Eng Chong Tan, Anders Poulsen, Pondy Murugappan Ramanujulu, Wee Joo Chng, J. J. Yen, Brian Dymock   +7 more
openalex   +1 more source

Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review

JEADV Clinical Practice, EarlyView.
ABSTRACT In recent years, innovative topical medications with novel mechanisms of action have emerged to treat common dermatologic conditions such as acne, atopic dermatitis, vitiligo, and actinic keratoses. These molecularly targeted therapies offer improved safety and tolerability compared to traditional options like corticosteroids.
Mary Dyson, Kara Hurley, Hannah Chaudhury, Lara Shehadeh, Cameron West   +4 more
wiley   +1 more source

Effect of JAK inhibitors on release of CXCL9, CXCL10 and CXCL11 from human airway epithelial cells [PDF]

, 2015
Barnes, PJ, Donnelly, LE, Fenwick, PS, Macedo, P   +3 more
core   +1 more source

Characterization of Jak, STAT, and Src interactions in Head and Neck Squamous Cell Carcinoma [PDF]

, 2013
Recurrence of Head and Neck Squamous Cell Carcinoma (HNSCC) is common; thus, it is essential to improve the effectiveness and reduce toxicity of current treatments.
Jaseja, Reshma, Jaseja, Reshma
core  

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

JEADV Clinical Practice, EarlyView.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender, Rosalind Hughes, Brian Kirby   +2 more
wiley   +1 more source

Novel Topical Treatments for Itch

Dermatology and Therapy
The experience of itch often poses a burden on patient quality of life and has the capacity to inflict significant suffering. Topical therapies are a mainstay of treatment for many cutaneous and systemic diseases and afford patients the opportunity to ...
Rami H. Mahmoud, Omar Mahmoud, Georgia Biazus Soares, Gil Yosipovitch   +3 more
doaj   +1 more source